We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).
At each visit, we will collect your vials, and blood, and ask you questions about your health since the last visit. You will also learn how self-inject the study medication (taken subcutaneously in your arm, thigh, or belly). You may be asked to have a liver biopsy done if you have not had one previously and we'll take scans of your liver to monitor throughout the study.
Information provided upon request
Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
A Barritt
Medicine-Gastroenterology
Clinical or Medical
Interventional
Kidneys and Liver
24-1101